MedPath

Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis

Phase 2
Terminated
Conditions
Ulcerative Colitis
Interventions
Registration Number
NCT04987307
Lead Sponsor
Amgen
Brief Summary

The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).

Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in the opinion of the investigator, they may benefit from continued treatment. During the long-term period, participants randomized to efavaleukin alfa will remain on the same efavaleukin alfa blinded dose; participants randomized to placebo who achieved clinical response at week 12 will remain on placebo; and placebo non-responders (ie, participants randomized to placebo who did not achieve clinical response at week 12) will receive efavaleukin alfa in a blinded manner during continued treatment. All participants will complete a safety follow-up visit 6 weeks after their last dose of investigational product.

Detailed Description

Not available

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
224
Inclusion Criteria
  • Participant has provided informed consent prior to initiation of any study specific activities or procedures.

  • Men and women aged ≥ 18 to < 80 years at screening visit (≥ 19 to < 80 in South Korea).

  • Diagnosis of UC established ≥ 3 months prior to enrollment by clinical and endoscopic evidence and corroborated by a histopathology report. If a histopathology report is not available at screening, then additional biopsies may be taken during the screening period for local histopathology analysis to corroborate.

  • Moderately to severely active UC as defined by a modified Mayo score of 5 to 9, with a centrally read endoscopy subscore ≥ 2.

  • Has documentation of:

    • A surveillance colonoscopy (performed according to local standard) within 12 months of day 1 visit for participants with pancolitis of > 8 years duration, or participants with left-sided colitis of > 12 years duration, or participants with primary sclerosing cholangitis.
    • At the discretion of the investigator, a colonoscopy (instead of a rectosigmoidoscopy) may be performed as the screening endoscopy for this study.
    • For all other participants, up-to-date colorectal cancer surveillance (performed according to local standard). Participants who do not have a colonoscopy report available in source documentation will have a colonoscopy instead of rectosigmoidoscopy performed as the screening endoscopy for the study.
  • Participants must have demonstrated inadequate response, loss of response, or intolerance to at least 1 conventional therapy, biologic therapy, or targeted small molecule therapy (ie, Janus kinase [JAK]-inhibitor or or S1P modulators), as follows:

    1. Conventional therapy failed participants:

      • Corticosteroids (corticosteroid-refractory colitis, defined as signs and/or symptoms of active UC despite oral prednisone [or equivalent] at doses of at least 30 mg/day for a minimum of 2 weeks; or corticosteroid-dependent colitis, defined as: an inability to reduce corticosteroids below the equivalent of prednisone 10 mg/day within 3 months of starting corticosteroids without a return of signs and/or symptoms of active UC; or a relapse within 3 months of completing a course of corticosteroids).
      • History of intolerance of corticosteroids (including, but not limited to, Cushing's syndrome, osteopenia/ osteoporosis, hyperglycemia, or neuropsychiatric side-effects, including insomnia, associated with corticosteroid treatment).
      • Immunomodulators: signs and/or symptoms of persistently active disease despite at least 3 months treatment with one of the following at locally approved doses: oral azathioprine (eg, ≥ 1.5 mg/kg/day) or 6-mercaptopurine (eg, ≥ 0.75 mg/kg/day), or oral azathioprine or 6-mercatopurine within a therapeutic range as judged by thioguanine metabolite testing, or a combination of a thiopurine and allopurinol within a therapeutic range as judged by thioguanine metabolite testing.
      • History of intolerance to at least 1 immunomodulator (including but not limited to nausea/vomiting, abdominal pain, pancreatitis, liver function test abnormalities, and lymphopenia) and have neither failed nor demonstrated an intolerance to a biological medication (anti-tumor necrosis factor [TNF] antibody, anti-integrin antibody, or interleukin [IL]-12/23 antagonists) that is indicated for the treatment of UC.
    2. Biologic or targeted small molecule therapy failed participants: those who demonstrated inadequate response or loss of response or intolerance to biologic therapy for UC (eg, anti-TNF antibodies or IL-12/23 antagonists, anti-integrin antibodies) or targeted small molecules (eg, JAK inhibitors or S1P modulators). The therapy used to qualify the participant for entry into this category must be approved for the treatment of UC in the country of use, at the time of use. Participants must fulfil one of the following criteria:

      • Inadequate response: signs and symptoms of persistently active disease despite induction treatment at the approved induction dosing that was indicated in the product label at the time of use.
      • Loss of response: recurrence of signs and symptoms of active disease during approved maintenance dosing following prior clinical benefit (discontinuation despite clinical benefit does not quality as having failed or being intolerant to UC biological therapy, JAK inhibitor, or S1P modulators).
      • Intolerance: history of intolerance to infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, tofacitinib or other approved biologicals, JAK inhibitors or S1P modulators (including but not limited to infusion-related event, demyelination, congestive heart failure, or any other drug-related adverse event that led to a reduction in dose or discontinuation of the medication).
  • If receiving any of the following therapies, participants must have stable dosage for the specified duration:

    • 5-aminosalicylates (ASAs), stable dosage for ≥ 2 weeks prior to screening endoscopy.
    • Oral corticosteroids: prednisone ≤ 20 mg/day or its equivalent, stable dose for ≥ 2 weeks prior to screening endoscopy.
    • Budesonide: extended release tablets 9 mg/day [budensonide MMX], stable dose for ≥ 2 weeks prior to screening endoscopy.
    • Beclomethasone dipropionate: gastro-resistant prolonged-release tablet 5 mg/day, stable dose for >= 2 weeks prior to screening endoscopy.
    • Conventional immunomodulators: azathioprine, 6-mercaptopurine, methotrexate, stable dosage for ≥ 12 weeks prior to screening endoscopy.

Key

Exclusion Criteria
  • Diagnosis of Crohn's disease, inflammatory bowel disease unclassified (indeterminate colitis), microscopic colitis, ischemic colitis, or clinical findings suggestive of Crohn's disease.

  • Evidence of toxic megacolon, fulminant colitis, intra-abdominal abscess, or stricture/stenosis within the small bowel or colon.

  • Participant has had extensive surgery for UC (for example, subtotal colectomy), or is likely to require surgery for the treatment of UC during the study.

  • Currently receiving or had treatment within 12 months prior to screening with T cell depleting agents (eg, antithymocyte globulin, Campath).

  • Participant has received any of the following prescribed medication or therapy within the specified time period:

    • Anti TNF antibodies (eg, infliximab, adalimumab, golimumab) < 8 weeks prior to screening rectosigmoidoscopy.
    • Anti integrin antibodies (eg, vedolizumab) < 8 weeks prior to screening rectosigmoidoscopy.
    • IL 12/23 antagonist (eg, ustekinumab) < 8 weeks prior to screening rectosigmoidoscopy.
    • JAK inhibitors (eg, tofacitinib) < 4 weeks prior to screening rectosigmoidoscopy.
    • Any other commercially approved biologic agent or targeted small molecule < 8 weeks prior to screening rectosigmoidoscopy or < 5 half lives prior to screening rectosigmoidoscopy, whichever is longer
    • Immunomodulatory medications, including oral cyclosporine, intravenous cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, thalidomide < 4 weeks prior to screening rectosigmoidoscopy.
    • Any investigational biologic therapy within 8 weeks prior to screening rectosigmoidoscopy or < 5 half-lives prior to screening rectosigmoidoscopy, whichever is longer.
    • Has used apheresis (eg, Adacolumnâ apheresis) < 2 weeks prior to screening rectosigmoidoscopy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Arm D: PlaceboPlaceboPlacebo Q2W
Arm B: Efavaleukin alfaEfavaleukin alfaEfavaleukin alfa Dose 2 administered by SC injection Q2W
Arm C: Efavaleukin alfaEfavaleukin alfaEfavaleukin alfa Dose 3 administered by SC injection Q2W
Arm A: Efavaleukin alfaEfavaleukin alfaEfavaleukin alfa Dose 1 administered by SC injection once every two weeks (Q2W)
Primary Outcome Measures
NameTimeMethod
Number of Participants with Clinical Remission at Week 12Week 12
Secondary Outcome Measures
NameTimeMethod
Number of Participants with Endoscopic Remission at Week 12Week 12
Number of Participants with Symptomatic Remission at Week 12Week 12
Number of Participants with Combined Endoscopic Remission and Histologic Remission of the Colon Tissue at Week 12Week 12
Number of Participants with a Clinically Significant Change from Baseline in Histological Score at Week 12 as Measured by Geboes ScoreBaseline to Week 12
Number of Participants who Experience One or More Treatment-emergent Adverse EventsUp to 56 weeks
Number of Participants with Clinical Response at Week 12Week 12

Trial Locations

Locations (200)

Digestive Health Specialists of the Southeast

🇺🇸

Dothan, Alabama, United States

Birmingham Digestive Health Research, LLC

🇺🇸

Homewood, Alabama, United States

Arizona Health Research

🇺🇸

Mesa, Arizona, United States

Arizona Arthritis and Rheumatology Research, PLLC

🇺🇸

Phoenix, Arizona, United States

Southern California Research Center

🇺🇸

Coronado, California, United States

United Medical Doctors

🇺🇸

Los Alamitos, California, United States

Biopharma Informatic Incorporated

🇺🇸

Los Angeles, California, United States

Gastrointestinal Biosciences Clinical Trials Limited Liability Company

🇺🇸

Los Angeles, California, United States

University of California Irvine

🇺🇸

Orange, California, United States

Santa Maria Gastroenterology Medical Group

🇺🇸

Santa Maria, California, United States

Clinical Trials Management Services LLC

🇺🇸

Thousand Oaks, California, United States

Gastroenterology Center of Connecticut, PC

🇺🇸

Hamden, Connecticut, United States

West Central Gastroenterology

🇺🇸

Clearwater, Florida, United States

Homestead Associates In Research Inc

🇺🇸

Homestead, Florida, United States

Indian Health Service Health Research

🇺🇸

Kissimmee, Florida, United States

Lake Center for Clinical Research

🇺🇸

Lady Lake, Florida, United States

Auzmer Research

🇺🇸

Lakeland, Florida, United States

University of Miami Hospital and Clinic

🇺🇸

Miami, Florida, United States

Ocala Gastrointestinal Research, LLC

🇺🇸

Ocala, Florida, United States

AdventHealth Medical Group Gastroenterology and Hepatology

🇺🇸

Orlando, Florida, United States

Infigo Clinical Research

🇺🇸

Sanford, Florida, United States

Atlanta Gastroenterology Associates

🇺🇸

Atlanta, Georgia, United States

Columbus Regional Research Institute, LLC

🇺🇸

Columbus, Georgia, United States

Grand Teton Research Group

🇺🇸

Idaho Falls, Idaho, United States

Rush University Medical Center

🇺🇸

Chicago, Illinois, United States

Digestive Research Alliance of Michiana

🇺🇸

South Bend, Indiana, United States

University of Kansas Medical Center

🇺🇸

Kansas City, Kansas, United States

Mid-Atlantic GI Research, LLC

🇺🇸

Greenbelt, Maryland, United States

Harvard Medical School - Brigham and Womens Hospital

🇺🇸

Boston, Massachusetts, United States

University of Massachusetts Memorial Medical Center

🇺🇸

Worcester, Massachusetts, United States

University of Michigan

🇺🇸

Ann Arbor, Michigan, United States

Clinical Research Institute of Michigan

🇺🇸

Troy, Michigan, United States

West Michigan Clinical Research Center

🇺🇸

Wyoming, Michigan, United States

Southern Therapy and Advanced Research LLC - Jackson

🇺🇸

Jackson, Mississippi, United States

Gastrointestinal Associates Research, LLC

🇺🇸

Columbia, Missouri, United States

Bvl Clinical Research

🇺🇸

Liberty, Missouri, United States

Interspond - Las Vegas Medical Research

🇺🇸

Las Vegas, Nevada, United States

Sanmora Bespoke Clinical Research Solutions

🇺🇸

East Orange, New Jersey, United States

Aga Clinical Research Associates LLC

🇺🇸

Egg Harbor Township, New Jersey, United States

Affiliates in Gastroenterology Digestive Disease Research

🇺🇸

Florham Park, New Jersey, United States

Atlantic Digestive Health Institute

🇺🇸

Morristown, New Jersey, United States

Premier Health Research LLC

🇺🇸

Sparta, New Jersey, United States

University of New Mexico

🇺🇸

Albuquerque, New Mexico, United States

New York University Grossman School of Medicine and New York University Langone Hospitals

🇺🇸

Lake Success, New York, United States

Consultants for Clinical Research

🇺🇸

Cincinnati, Ohio, United States

Digestive Specialists Inc Research, LLC

🇺🇸

Springboro, Ohio, United States

Hightower Clinical

🇺🇸

Oklahoma City, Oklahoma, United States

Options Health Research, LLC

🇺🇸

Tulsa, Oklahoma, United States

Guthrie Robert Packer Hospital

🇺🇸

Sayre, Pennsylvania, United States

Medical University of South Carolina

🇺🇸

Charleston, South Carolina, United States

Columbia Digestive Health Research LLC

🇺🇸

Columbia, South Carolina, United States

Wake Research-ClinSearch, LLC

🇺🇸

Chattanooga, Tennessee, United States

Digestive Health Research, LLC

🇺🇸

Hermitage, Tennessee, United States

Great Lakes Research Insititute El Paso Research

🇺🇸

El Paso, Texas, United States

Digestive Health Associates

🇺🇸

Houston, Texas, United States

Digestive Research of Central Texas, LLC

🇺🇸

Waco, Texas, United States

Digestive Health Research of North Texas LLC

🇺🇸

Wichita Falls, Texas, United States

Emeritas Research Group

🇺🇸

Lansdowne Town Center, Virginia, United States

Blue Ridge Medical Research

🇺🇸

Lynchburg, Virginia, United States

North Richmond Health Research

🇺🇸

Richmond, Virginia, United States

GI Select Health Research LLC

🇺🇸

Richmond, Virginia, United States

Hunter Holmes McGuire Veterans Affairs Medical Center

🇺🇸

Richmond, Virginia, United States

Wisconsin Center for Advanced Research

🇺🇸

Milwaukee, Wisconsin, United States

Centro de Investigaciones Medicas Mar del Plata

🇦🇷

Mar del Plata, Buenos Aires, Argentina

Clinica Independencia

🇦🇷

Munro, Buenos Aires, Argentina

Cer Instituto Medico

🇦🇷

Quilmes, Buenos Aires, Argentina

CardioAlem Investigaciones

🇦🇷

San Isidro, Buenos Aires, Argentina

Hospital Privado Centro Medico de Cordoba SA

🇦🇷

Cordoba, Córdoba, Argentina

Fundacion Estudios Clinicos

🇦🇷

Rosario, Santa Fe, Argentina

Medizinische Universitaet Innsbruck

🇦🇹

Innsbruck, Austria

Landeskrankenhaus Salzburg

🇦🇹

Salzburg, Austria

Universitaetsklinikum Allgemeines Krankenhaus Wien

🇦🇹

Wien, Austria

Universitair Ziekenhuis Antwerpen

🇧🇪

Edegem, Belgium

Universitair Ziekenhuis Leuven - Campus Gasthuisberg

🇧🇪

Leuven, Belgium

Centre Hospitalier Universitaire de Liege - Sart Tilman

🇧🇪

Liège, Belgium

Second Multiprofile Hospital for Active Treatment - Sofia EAD

🇧🇬

Sofia, Bulgaria

Diagnostic-Consultative Center Convex EOOD

🇧🇬

Sofia, Bulgaria

Acibadem City Clinic University Multiprofile Hospital for Active Treatment Mladost EOOD

🇧🇬

Sofia, Bulgaria

South Edmonton Gastroenterology

🇨🇦

Edmonton, Alberta, Canada

London Health Sciences Centre, University Hospital

🇨🇦

London, Ontario, Canada

TIDHI Innovation Incorporated

🇨🇦

Toronto, Ontario, Canada

Hepato-Gastroenterologie HK sro

🇨🇿

Hradec Kralove, Czechia

Nemocnice Pardubickeho kraje as, Pardubicka nemocnice

🇨🇿

Pardubice, Czechia

Nemocnice Milosrdnych sester sv Karla Boromejskeho v Praze

🇨🇿

Praha, Czechia

Axon Clinical sro

🇨🇿

Praha, Czechia

Krajska zdravotni as - Masarykova nemocnice Usti nad Labem oz

🇨🇿

Usti nad Labem, Czechia

Aalborg Universitetshospital

🇩🇰

Aalborg, Denmark

Herlev Hospital

🇩🇰

Herlev, Denmark

Hvidovre Hospital

🇩🇰

Hvidovre, Denmark

Bispebjerg Hospital

🇩🇰

Kobenhavn NV, Denmark

Helsinki University Central Hospital

🇫🇮

Helsinki, Finland

Centre Hospitalier Universitaire Amiens Picardie

🇫🇷

Amiens cedex 1, France

Centre Hospitalier Universitaire de Montpellier - Hopital Saint Eloi

🇫🇷

Montpellier cedex 5, France

Centres Medicaux Chirurgicaux Ambroise Pare Hartmann

🇫🇷

Neuilly sur seine, France

Centre Hospitalier Universitaire Archet 2

🇫🇷

Nice cedex 3, France

Centre Hospitalier Universitaire Nord de Saint Etienne - Hopital Nord

🇫🇷

Saint Priest en Jarez, France

Centre Hospitalier Universitaire de Nancy - Hôpital de Brabois

🇫🇷

Vandoeuvre les Nancy Cedex, France

Gastro-Studien GbR Studienzentrum

🇩🇪

Berlin, Germany

Universitaetsklinikum Essen

🇩🇪

Essen, Germany

Universitaetsklinikum Frankfurt

🇩🇪

Frankfurt am Main, Germany

Universitaetsklinikum Schleswig-Holstein

🇩🇪

Kiel, Germany

Universitaetsklinikum Tuebingen

🇩🇪

Tuebingen, Germany

Universitaetsklinikum Ulm

🇩🇪

Ulm, Germany

University General Hospital of Alexandroupolis

🇬🇷

Alexandroupoli, Greece

General Hospital Evangelismos

🇬🇷

Athens, Greece

Laiko General Hospital of Athens

🇬🇷

Athens, Greece

University Hospital Attikon

🇬🇷

Haidari, Greece

Venizeleio General Hospital

🇬🇷

Heraklion, Greece

University Hospital of Heraklion

🇬🇷

Heraklion, Greece

University General Hospital of Ioannina

🇬🇷

Ioannina, Greece

General University Hospital of Patras Panagia i Voithia

🇬🇷

Patras, Greece

Bekes Varmegyei Kozponti Korhaz Dr Rethy Pal Tagkorhaz

🇭🇺

Bekescsaba, Hungary

MIND Klinika Kft

🇭🇺

Budapest, Hungary

Clinexpert Kft

🇭🇺

Budapest, Hungary

Obudai Egeszsegugyi Centrum Kft

🇭🇺

Budapest, Hungary

Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont Altalanos Orvostudomanyi Kar

🇭🇺

Szeged, Hungary

Clinfan Kft

🇭🇺

Szekszard, Hungary

Komarom-Esztergom Varmegyei Szent Borbala Korhaz

🇭🇺

Tatabanya, Hungary

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

🇮🇹

Brescia, Italy

Azienda Ospedaliera Universitaria Renato Dulbecco

🇮🇹

Catanzaro, Italy

Azienda Ospedaliero Universitaria Careggi

🇮🇹

Firenze, Italy

Ospedale Policlinico San Martino IRCCS

🇮🇹

Genoa, Italy

Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico

🇮🇹

Milano, Italy

IRCCS Ospedale San Raffaele

🇮🇹

Milano, Italy

Ospedale Sacro Cuore Don Calabria

🇮🇹

Negrar VR, Italy

Ospedale Sandro Pertini

🇮🇹

Roma, Italy

Tsujinaka Hospital Kashiwanoha

🇯🇵

Kashiwa-shi, Chiba, Japan

Toho University Sakura Medical Center

🇯🇵

Sakura-shi, Chiba, Japan

Kitakyushu Municipal Medical Center

🇯🇵

Kitakyushu-shi, Fukuoka, Japan

Gifu University Hospital

🇯🇵

Gifu-shi, Gifu, Japan

Matsunami General Hospital

🇯🇵

Hashima-gun, Gifu, Japan

Hakodate Central General Hospital

🇯🇵

Hakodate-shi, Hokkaido, Japan

Sapporo Tokushukai Hospital

🇯🇵

Sapporo-shi, Hokkaido, Japan

Aoyama Clinic GI Endoscopy and IBD Center

🇯🇵

Kobe-shi, Hyogo, Japan

Gokeikai Ofuna Chuo Hospital

🇯🇵

Kamakura-shi, Kanagawa, Japan

Takagi Clinic

🇯🇵

Sendai-shi, Miyagi, Japan

Miyazaki Prefectural Miyazaki Hospital

🇯🇵

Miyazaki-shi, Miyazaki, Japan

Nagasaki University Hospital

🇯🇵

Nagasaki-shi, Nagasaki, Japan

Nara Medical University Hospital

🇯🇵

Kashihara-shi, Nara, Japan

National Hospital Organization Okayama Medical Center

🇯🇵

Okayama-shi, Okayama, Japan

Osaka Metropolitan University Hospital

🇯🇵

Osaka-shi, Osaka, Japan

Tokyo Medical and Dental University Hospital

🇯🇵

Bunkyo-ku, Tokyo, Japan

Kitasato University Kitasato Institute Hospital

🇯🇵

Minato-ku, Tokyo, Japan

Kyorin University Hospital

🇯🇵

Mitaka-shi, Tokyo, Japan

Ome Medical Center

🇯🇵

Ome-shi, Tokyo, Japan

Medical Corporation ENEXT Ikebukuro West Gate Hospital

🇯🇵

Toshima-ku, Tokyo, Japan

Yamanashi Prefectural Central Hospital

🇯🇵

Kofu-shi, Yamanashi, Japan

Inje University Haeundae Paik Hospital

🇰🇷

Busan, Korea, Republic of

Yeungnam University Medical Center

🇰🇷

Daegu, Korea, Republic of

Samsung Medical Center

🇰🇷

Seoul, Korea, Republic of

The Catholic University of Korea Seoul St Marys Hospital

🇰🇷

Seoul, Korea, Republic of

Wonju Severance Christian Hospital

🇰🇷

Wonju-si, Gangwon-do, Korea, Republic of

Pauls Stradins Clinical University Hospital

🇱🇻

Riga, Latvia

Gastro Centrs

🇱🇻

Riga, Latvia

Clinicos Asociados BOCM SC

🇲🇽

Ciudad de Mexico, Distrito Federal, Mexico

Clinica de Investigacion en Reumatologia y Obesidad SC

🇲🇽

Guadalajra, Jalisco, Mexico

Investigacion Biomedica para el Desarrollo de Farmacos SA de CV

🇲🇽

Zapopan, Jalisco, Mexico

CRI Centro Regiomontano de Investigacion SC

🇲🇽

Monterrey, Nuevo León, Mexico

Hospital San Jose Tec Salud Fundacion Santos y de la Garza Evia IBP

🇲🇽

Monterrey, Nuevo León, Mexico

Centro para el Desarrollo de la Medicina y de Asistencia Medica Especializada SC

🇲🇽

Culiacan, Sinaloa, Mexico

Leids Universitair Medisch Centrum

🇳🇱

Leiden, Netherlands

Elisabeth TweeSteden Ziekenhuis

🇳🇱

Tilburg, Netherlands

Universitair Medisch Centrum Utrecht

🇳🇱

Utrecht, Netherlands

NZOZ Twoje Zdrowie EL Spzoo

🇵🇱

Elblag, Poland

Centrum Medyczne Med-Gastr Sp zoo

🇵🇱

Lodz, Poland

Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Spzoo

🇵🇱

Malbork, Poland

Oleg Tyszkiwski Centrum Gastrologiczne Gorczyn Oleg Tyszkiwski

🇵🇱

Poznan, Poland

Centrum Medyczne Pratia Poznan

🇵🇱

Skorzewo, Poland

BodyClinic spolka z ograniczona odpowiedzialnoscia

🇵🇱

Warszawa, Poland

Centrum Medyczne Melita Medical

🇵🇱

Wroclaw-Krzyki, Poland

EuroMediCare Przychodnia Specjalistyczna we Wroclawiu

🇵🇱

Wroclaw, Poland

Institutul Clinic Fundeni

🇷🇴

Bucharest, Romania

Spitalul Universitar de Urgenta Militar Central Dr Carol Davila

🇷🇴

Bucuresti, Romania

Clinica Medicum

🇷🇴

Bucuresti, Romania

Memorial Healthcare International SRL

🇷🇴

Bucuresti, Romania

Spitalul Clinic Colentina

🇷🇴

Bucuresti, Romania

Spitalul Clinic Pelican

🇷🇴

Oradea, Romania

Fakultna Nemocnica s poliklinikou FD Roosevelta Banska Bystrica

🇸🇰

Banska Bystrica, Slovakia

Endomed, sro

🇸🇰

Kosice, Slovakia

Gastro I, sro

🇸🇰

Presov, Slovakia

Hospital de la Santa Creu i Sant Pau

🇪🇸

Barcelona, Cataluña, Spain

Hospital Universitario de La Princesa

🇪🇸

Madrid, Spain

Hospital General Universitario Gregorio Marañon

🇪🇸

Madrid, Spain

Hospital Universitario La Paz

🇪🇸

Madrid, Spain

Inselspital Bern

🇨🇭

Bern, Switzerland

Intesto BE

🇨🇭

Bern, Switzerland

Kantonsspital St Gallen

🇨🇭

Sankt Gallen, Switzerland

Universitaetsspital Zuerich

🇨🇭

Zuerich, Switzerland

China Medical University Hospital

🇨🇳

Taichung, Taiwan

National Taiwan University Hospital

🇨🇳

Taipei, Taiwan

Taipei Veterans General Hospital

🇨🇳

Taipei, Taiwan

Ankara Bilkent Sehir Hastanesi

🇹🇷

Ankara, Turkey

Antalya Egitim ve Arastirma Hastanesi

🇹🇷

Antalya, Turkey

Uludag Universitesi Tip Fakultesi Hastanesi

🇹🇷

Bursa, Turkey

Gaziantep Universitesi Tip Fakultesi Hastanesi

🇹🇷

Gaziantep, Turkey

Istanbul Universitesi Istanbul Tip Fakultesi Hastanesi

🇹🇷

Istanbul, Turkey

Ege Universitesi Tip Fakultesi Hastanesi

🇹🇷

Izmir, Turkey

Dokuz Eylul Universitesi Tip Fakultesi Hastanesi

🇹🇷

Izmir, Turkey

Kocaeli Universitesi Tip Fakultesi Hastanesi

🇹🇷

Kocaeli, Turkey

Mersin Universitesi Tip Fakultesi Hastanesi

🇹🇷

Mersin, Turkey

© Copyright 2025. All Rights Reserved by MedPath